Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. (Q51778586)
Jump to navigation
Jump to search
scientific article published on 14 January 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. |
scientific article published on 14 January 2010 |
Statements
1 reference
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. (English)
1 reference
B Keymeulen
1 reference
M Walter
1 reference
C Mathieu
1 reference
L Kaufman
1 reference
F Gorus
1 reference
R Hilbrands
1 reference
E Vandemeulebroucke
1 reference
U Van de Velde
1 reference
C De Block
1 reference
S Candon
1 reference
A G Ziegler
1 reference
L Chatenoud
1 reference
D Pipeleers
1 reference
14 January 2010
1 reference
1 reference
53
1 reference
614-623
1 reference
4
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference